Fig. 2From: Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO studyInvestigator-assessed PFS in the Pt-S treatment subgroup (n = 7) and the Pt-R treatment subgroup (n = 26). CI: confidence interval; mPFS: median progression-free survival; Tx Pt-S: treatment, platinum-sensitive disease; Tx Pt-R: treatment, platinum-resistant disease; +: censored patientsBack to article page